|Bid||3.0300 x 676100|
|Ask||3.0400 x 1520800|
|Day's range||2.9200 - 3.0600|
|52-week range||2.7800 - 5.5400|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||6.06|
|Earnings date||21 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||0.12 (4.11%)|
|Ex-dividend date||07 Sept 2022|
|1y target est||3.56|
SYDNEY, Australia & BELMONT, Calif., November 02, 2022--Healius Limited (Healius) (ASX: HLS), one of Australia’s leading healthcare companies, has selected RingCentral, Inc. (NYSE: RNG) to deploy an integrated unified communications as a service (UCaaS) and contact center as a service (CCaaS) solution. This technology investment is designed to improve the doctor and patient experience in Healius’ pathology and diagnostic imaging practices through improvements in communications, initially within
ST. LOUIS, August 30, 2022--C2N Diagnostics, a leader in advanced brain health diagnostics, and Healius Ltd (ASX:HLS), one of Australia's leading listed healthcare companies, today announced a partnership that will aim to bring C2N’s PrecivityAD™ blood test and related brain health biomarkers to the forefront of memory and dementia care in Australia. The partnership represents C2N’s first international country-wide agreement as it expands its offerings beyond the United States and Europe.
In this article we are going to estimate the intrinsic value of Healius Limited ( ASX:HLS ) by projecting its future...